Predatory patent litigation
نویسندگان
چکیده
s included below are as written by the author(s) and are unedited.
منابع مشابه
Analysis of the Relationship between Patent Litigation and Citation: Subdivision of Citations
Recent examples of patent litigation show the evidence of firms strategic patent use. Thus forecasting patent litigation becomes a greater priority. Patent citations have been prevalent in its usage in analyzing business environment as diverse patent indicators or a tool to predict patent litigation. However, most previous research has considered only direct patent citations. In order to overco...
متن کاملThe Rise of Contingent Fee Representation in Patent Litigation
It is well known that plaintiff-side contingent representation is on the rise in patent litigation. But why? And what are the lawyers in the field like? Although scholars have studied contingent litigation in other contexts — such as medical malpractice, personal injury, and products liability litigation — patent litigation has received almost no attention. This gap in the literature is unsettl...
متن کاملThe Causes and Economic Consequences of Patent Litigation
JEL Classification O34, K41, G24, M41, M42. A survey of patent litigation in the Taiwan electronics industry between 2010 and 2015 provides insight into the causes and economic consequences of patent litigation. This survey had three key what were the findings of this study? First, companies with patents for new inventions are more likely to file plaintiff-initiated lawsuits and less likely to ...
متن کاملGAT, Solvay, and the Centralization of Patent Litigation in Europe
As business has become global, so have disputes about patents, patent infringement, and patent validity. In many ongoing disputes between patent holders and alleged infringers, parties are engaging in parallel court proceedings in multiple countries to litigate infringements of parallel patents and to contest the validity of patents. Concentrating litigation involving identical inventions and i...
متن کاملHow amending ANDA specifications can win or lose pharmaceutical patent litigation
Martin S. Masar III (L), an associate with Katten Muchin Rosenman in Chicago, has a variety of experience in patent litigation and prosecution, as well as in other areas of intellectual property and antitrust litigation. His practice focuses on chemistry, pharmaceutical arts, nanotechnology and biotechnology. Thomas J. Maas (R), an associate with the firm, concentrates his practice on resolving...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013